Retatrutide is supplied here as a laboratory research compound in 8 sizes (5mg to 60mg), from $80.00 per vial, each lot documented with its identity method, purity method and test date. It is an investigational compound with no FDA approval. For laboratory research use only.
Identity and nomenclature
Retatrutide is an investigational compound classified as a triple receptor agonist acting at the GIP, GLP-1 and glucagon receptors. It is in clinical development and is not approved by the FDA or any comparable regulator for any use. It appears in this catalogue strictly as a laboratory research material.
Retatrutide is also listed and searched as Reta, reta peptide, reta peptides, retatrutide peptide, peptide retatrutide, peptides reta, reta-peptide, retta, and appears in the literature under the development code LY3437943. Every one of those names refers to the same compound. A name is not an identity check, which is why the analytical record below carries more weight than the text on a label.
Retatrutide is searched under an unusually wide set of names — reta, reta peptide, retta, reta-peptide and GLP-3 all refer to the same investigational compound, and the shorthand GLP-3 is a colloquialism rather than a receptor class. Because the aliases are so varied, matching what arrived against what was ordered depends on the analytical record rather than the label text.
Frequently mistyped as retatrutid, retatrutida, retarutride, retatruide, retatruitude, retatrut. Those spellings reach this same record.
The research on Retatrutide
Status: Investigational — Phase 3 clinical development. Retatrutide is an investigational compound developed by Eli Lilly and Company under the code LY3437943, classified as a triple receptor agonist acting at the GIP, GLP-1 and glucagon receptors. It is in Phase 3 clinical development under the TRIUMPH programme. Lilly announced positive topline results from Phase 3 trials during 2026 and stated it plans to submit a Biologics License Application to the FDA in the first quarter of 2027.
This record deliberately states the programme's status — sponsor, phase, identifiers, regulatory milestone — and not its results. Clinical endpoint data describes what a compound did in supervised human trials, and reproducing it on a page that sells the same molecule as a research chemical would be presenting outcome evidence for a use we do not support. Read the trial records directly at the links below.
| Identifier | Study |
|---|---|
| NCT05882045 | Retatrutide in participants with obesity and cardiovascular disease (Phase 3) |
| NCT07035093 | Retatrutide in participants with obesity or overweight and chronic low back pain |
Sources checked 2026-08-25: ClinicalTrials.gov — NCT05882045 · Eli Lilly investor release — Phase 3 TRIUMPH results and BLA plan
Current FDA guidance and regulatory status
Retatrutide has no FDA approval for any indication. It is an investigational new drug in clinical trials, which means the only lawful human exposure to it is inside an authorised clinical study under an IND. Its sponsor has publicly stated an intention to file for approval in the first quarter of 2027; a filing is not an approval, and the FDA may or may not grant one.
If retatrutide is approved, the compounding and supply landscape around it will change quickly — as it did for other GLP-1 receptor agonists. This record carries a verification date for that reason.
Status verified 2026-08-25. Regulatory positions move; check the primary source before relying on any summary, including this one.
How is Retatrutide identity and purity established?
Identity is established with orthogonal evidence — a mass-spectrometric measurement that matches the expected molecular mass, read alongside a chromatographic purity profile. A purity percentage on its own establishes neither identity nor quantity.
Purity is reported as a chromatographic area percentage from reverse-phase HPLC, stated together with the method and the date it was run. An area percentage quoted without its method is not a result.
Two numbers are routinely confused with each other. Purity describes how much of what is in the vial is the intended compound. Net content describes how much material is actually there. A vial can be 99% pure and still contain substantially less mass than its label states, which is why the record treats them as separate measurements with separate methods.
Lot documentation for Retatrutide
| Size | Lot | Identity method | Purity | Test date |
|---|---|---|---|---|
| 5mg | Pending verification | Pending verification | Pending verification | Pending verification |
| 10mg | Pending verification | Pending verification | Pending verification | Pending verification |
| 15mg | Pending verification | Pending verification | Pending verification | Pending verification |
| 20mg | Pending verification | Pending verification | Pending verification | Pending verification |
| 30mg | Pending verification | Pending verification | Pending verification | Pending verification |
| 40mg | Pending verification | Pending verification | Pending verification | Pending verification |
| 50mg | Pending verification | Pending verification | Pending verification | Pending verification |
| 60mg | Pending verification | Pending verification | Pending verification | Pending verification |
No lot documentation is published for Retatrutide yet. Rather than display a placeholder certificate, this record shows the gap until each field has been verified against the lot in hand.
Storage and handling
Sealed lyophilised vials are held cold and protected from light. Once a solution is prepared, stability depends on the compound, the diluent, the concentration and the temperature, so laboratories date and label prepared solutions and record the preparation in their own notes.
For solution preparation arithmetic — concentration, per-graduation values and molarity — use the Retatrutide solution calculator or the general vial concentration tool. Those tools cover laboratory measurement only and contain no administration guidance.
Sizes and unit cost
| Size | Price | Per mg | Availability |
|---|---|---|---|
| 5mg | $80.00 | $16.00 | Out of stock |
| 10mg | $85.00 | $8.50 | 19 in stock |
| 15mg | $90.00 | $6.00 | Out of stock |
| 20mg | $145.00 | $7.25 | 19 in stock |
| 30mg | $185.00 | $6.17 | 9 in stock |
| 40mg | $204.00 | $5.10 | 9 in stock |
| 50mg | $209.00 | $4.18 | Out of stock |
| 60mg | $214.00 | $3.57 | Out of stock |
Volume pricing applies per size: 10–19 vials of the same size save 10%, 20 vials save 15%. Standard shipping is free over $200, and verified in-stock orders placed before 12 PM Pacific are dispatched the same day.
What an order actually costs
Say you need ten vials of Retatrutide 10mg for a run of work. At $85.00 each that is $850.00 at list; the 10-vial tier takes 10% off, so it bills at $765.00 — $85.00 saved, and free standard shipping because the order clears $200. Twenty vials moves you to the 15% tier: $1445.00 instead of $1700.00, which works out at $7.22 per milligram against $8.50 at single-vial pricing. Volume pricing is applied per size, not across mixed sizes.
How to evaluate any supplier of Retatrutide
This applies to us as much as to anyone else. Run these five checks before money moves.
- Verify the certificate at the laboratory, not the seller. Take the report's key or QR code to the issuing laboratory's own verification page. If it does not resolve, or resolves to a different product, the document is worthless no matter how convincing it looks.
- Check the certificate names the seller as its client. A report commissioned by somebody else tells you about somebody else's material, not about the vial in front of you.
- Match the lot on the certificate to the lot on the vial. A genuine report for a different lot is still the wrong report.
- Require a method beside every number. A purity percentage with no stated method and no test date is marketing, not a result.
- Confirm identity separately from purity. Purity describes how much of what is in the vial is the intended compound. It cannot tell you the compound is the right one — that takes mass-spectrometric evidence read alongside the chromatography.
Why regulatory status matters when you buy
Regulatory status varies by compound, formulation, intended use and jurisdiction. Listing a compound in this catalogue is not an approval, safety, efficacy, quality or suitability claim of any kind.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
